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Mortality Assessment of Paclitaxel-Coated
Balloons
Patient-Level Meta-Analysis of the ILLUMENATE Clinical
Program at 3 Years
BACKGROUND: A recent summary-level meta-analysis comprising randomized,
controlled trials (RCTs) of femoropopliteal paclitaxel-coated balloon and stent
intervention identified excess late mortality in the paclitaxel-treated patients.
METHODS: We evaluated the safety of the Stellarex drug-coated balloon (DCB) for
femoropopliteal artery disease with an independently performed meta-analysis of
patient-level data from all patients in the Stellarex femoropopliteal clinical program.
To compare mortality after DCB or uncoated percutaneous transluminal angioplasty
(PTA), we aggregated data from 2 RCTs comprising 419 patients treated with DCB
and 170 patients treated with PTA. In an additional analysis, data were aggregated
from 6 poolable Stellarex DCB studies (2 RCTs, 3 single-arm studies, and 1 registry).
All serious adverse events including deaths were adjudicated by a blinded, thirdparty, independent Clinical Events Committee. Kaplan–Meier estimates in the
RCTs were compared with restricted mean survival time. Predictors of death were
assessed with hazard ratios (HRs) and Cox proportional hazards modeling.
RESULTS: Baseline characteristics were similar in the patients treated with DCB
and PTA in the pooled RCT analysis, with the exception that the DCB cohort was
younger (67.4±9.7 versus 69.4±9.4 years, P=0.02), smoked more frequently
(86.6% versus 78.8%, P=0.02), and were less often treated for recurrent lesions
(8.8% versus 14.7%, P=0.04). In the RCTs, patients treated with DCB had allcause mortality rates that were not different from those of patients treated with
PTA (Kaplan–Meier estimates 1.8±0.7% versus 1.3±0.9%, 6.5±1.2% versus
5.9±1.9%, and 9.3±1.5% versus 9.9±2.4% at 1, 2, and 3 years, respectively,
P=0.86). All-cause mortality rates were similar in a 1906-patient pooled
nonrandomized DCB data set (Kaplan–Meier estimates of 2.1%, 4.9%, and
7.0% at 1, 2, and 3 years, respectively). Clinical Events Committee–adjudicated
causes of death were balanced between the DCB and PTA cohorts. Multivariable
Cox modeling identified age (HR, 1.06; 95% CI, 1.04–1.08; P<0.001), diabetes
mellitus (HR, 1.42; 95% CI, 1.01–2.00; P=0.04), congestive heart failure (HR,
1.88; 95% CI, 1.12–3.16; P=0.02), and renal insufficiency (HR, 2.00; 95% CI,
1.33–3.01; P<0.001) as predictors of mortality. Paclitaxel exposure was unrelated
to mortality (HR, 1.04; 95% CI, 0.98–1.10; P=0.23).
CONCLUSIONS: The mortality rates for patients treated with the DCB and
uncoated PTA were indistinguishable over 3-year follow-up. Additional patientlevel, adequately powered meta-analyses with larger RCT data sets will be
needed to confirm the generalizability of these findings.
CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique
identifiers: NCT02110524, NCT01858363, NCT01858428, NCT03421561,
NCT01912937, NCT01927068, and NCT02769273.
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Analysis of Mortality in SFA DCB Therapy

Clinical Perspective
What Is New?
• A patient-level meta-analysis of 2 randomized,
controlled trials has been conducted from the ILLUMENATE clinical program that demonstrated no
difference in mortality when the Stellarex paclitaxelcoated balloon was compared with uncoated percutaneous transluminal angioplasty through 3 years.
• A paclitaxel dose–dependent effect was also not
evident.
• The use of Stellarex paclitaxel-coated balloon has
not correlated to late all-cause mortality.

What Are the Clinical Implications?
• Paclitaxel-coated balloons have been suggested to
be a factor in late all-cause mortality at 2 and 5
years posttreatment.
• The implication derives from a meta-analysis published by Katsanos et al in 2018.
• Although the relationship of paclitaxel use and
mortality was found to be statistically significant in
that meta-analysis, the causal relationship has not
been established.
• Although freedom from target lesion revascularization is improved with the use of a paclitaxel-coated
balloon, the relationship to late all-cause mortality
must be determined.

P

ercutaneous transluminal angioplasty (PTA) has
long been a mainstay of femoropopliteal peripheral
arterial disease (PAD) treatment.1 As a minimally invasive modality, PTA has advantages over open surgical
revascularization and avoids the obligatory, systematic
need for implantation of a permanent metallic arterial
stent.2 The durability of femoropopliteal PTA, however,
is not ideal. When patients with femoropopliteal disease
are treated with uncoated balloons, up to 47.4% experience restenosis in the first year after treatment.3
Drug-coated balloons (DCBs) are effective in treating de novo or restenotic lesions of the femoropopliteal
arteries.4 Paclitaxel is a cytostatic and cytotoxic agent
widely used to treat various malignancies, and its therapeutic window and pharmacokinetic behavior is welldescribed.5 Paclitaxel has significantly decreased the
risk of restenosis when delivered to the vessel wall with
DCBs and drug-eluting stents in patients with femoropopliteal disease. In previous studies, patients who were
treated with DCBs had improved target vessel patency
and significant reductions in late lumen loss and target vessel revascularization in comparison with patients
treated with PTA.6–10 Current Society for Cardiovascular
Angiography and Interventions guidelines recommend
DCB as a standard treatment option for femoropopliteal artery disease.11
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A recent systematic review and meta-analysis of
summary-level data from 28 randomized, controlled
trials (RCTs) suggested an increased risk of death after
femoropopliteal artery DCB beginning 2 years after the
DCB procedure.12 Furthermore, the risk of death was
incrementally associated with exposure to paclitaxel,
leading the authors to speculate that late paclitaxel
toxicity may be contributing to the observed higher
mortality. This analysis has been criticized for its lack of
long-term, homogeneous, patient-level data that might
have identified confounding factors to better explain
the observations.12
The present study examines the safety profile of the
Stellarex DCB in comparison with uncoated PTA, analyzing patient-level data from the worldwide Stellarex
femoropopliteal clinical trials. The study was designed to
avoid many of the limitations of the recently published,
summary-level meta-analysis. An independent third party, Syntactx, performed the analysis using patient-level
data and cause-specific adjudicated deaths, homogeneous populations treated with the same paclitaxelcoated device, and 3-year follow-up after treatment.

METHODS
Data Sources
Because of the sensitive nature of the data collected for
this study, requests to access the data set from qualified
researchers trained in human subject confidentiality protocols
may be sent to Philips, IGT-D Medical Information Services
Department at 1-877-878-0012 or medicalinformation.services@philips.com.
The study population comprised 2523 patients: 2353
treated with the DCB and 170 treated with uncoated PTA. The
data set included the 7 studies that comprised the Stellarex
femoropopliteal clinical program (Table 1). The ILLUMENATE
EU RCT trial (CVI Drug-coated Balloon European Randomized
Clinical Trial) and the ILLUMENATE Pivotal trial (Pivotal Trial of
Table 1. Patient Cohorts From the Stellarex Femoropopliteal Clinical
Program
Study
Design

Patients
Included

Geography

FollowUp, mo

ILLUMENATE EU
RCT

RCT

289

Europe

60

ILLUMENATE
Pivotal9

RCT

300

United States,
Europe

60

ILLUMENATE
Global13

Single-arm

372

Europe, New
Zealand, Australia

60

ILLUMENATE
Global ISR

Single-arm

112

Europe, New
Zealand, Australia

60

ILLUMENATE PK9

Single-arm

25

New Zealand

24

ILLUMENATE FIH14

Single-arm

79

Europe

24

SAVER Registry

Single-arm

1346

Unspecified

36

Study

FIH indicates first in human; ISR, in-stent restenosis; PK, pharmacokinetic;
and RCT, randomized, controlled trial.
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Interventions
The 0.035-inch platform DCB was used for intervention in all
studies. The device is intended for use in patients with PAD
to treat de novo or restenotic lesions. The DCB consists of an
over-the-wire dual-lumen catheter with a distally mounted
semicompliant inflatable balloon and an atraumatic tapered
tip. The balloon’s proprietary coating (EnduraCoat) contains a
hybrid balance of amorphous and crystalline paclitaxel at a uniform concentration of 2 µg/mm2 as the active pharmaceutical
agent with a polyethylene glycol excipient. Preclinical evidence
demonstrated high coating stability with limited distal embolization and high drug transfer efficiency.15 A minimum inflation
time of 60 seconds is recommended in the instructions for use.

Outcomes
The outcome for the meta-analysis is time to death. Patients
who did not reach the end point by 3 years were censored
at their last day of contact or 3 years, whichever came first.
Deaths were adjudicated by the independent CEC (see the
online-only Data Supplement Appendix). Causes of death were
classified by a designated Safety Officer, using the Medical
Dictionary for Regulatory Activities (MedDRA) terminology
(version 21.0, MedDRA MSSO) System Organ Classes. CECadjudicated deaths were grouped into those that were cardiovascular-related or non–cardiovascular-related. Undetermined
causes of death were classified as non–cardiovascular-related.

Statistical Methods
A key objective of this investigation was to develop a model of
predictors of the mortality in patients treated with DCBs. The
hazard rate for mortality (MHR) was used to assess mortality
in the 7 Stellarex studies. Unlike the hazard ratio (HR), which
Circulation. 2019;140:1145–1155. DOI: 10.1161/CIRCULATIONAHA.119.040518

compares 2 groups like test versus control, the MHR measures
the instantaneous speed at which deaths are accumulating over
time for the population being evaluated. To assess the heterogeneity of outcome among the studies, a 2-stage meta-analysis of individual patient data was performed by using Stata/IC
(version 15.1, StataCorp LLC). The I2 statistic was calculated to
assess the percentage of variation across studies attributable to
heterogeneity rather than chance alone.16
The Student t test was used for comparisons of continuous variables and the Fisher exact test was used for categorical
variables. Continuous variables were presented as mean±SD or
median (range). Kaplan–Meier methodology was used to estimate hazard rates of all-cause mortality, and the restricted mean
survival time was used to compare outcome in the randomized
treatment arms. Cox proportional hazards modeling was used
to assess the relationship between baseline and demographic
characteristics and mortality. Candidate variables included baseline and demographic characteristics, treatment (DCB or PTA),
and paclitaxel exposure. Exposure, the total amount of drug
per patient, was calculated by size (diameter and length) and
the number of devices used during treatment. A univariate Cox
model was done for each candidate variable. Variables with
>15% of values missing were excluded. Imputation of missing
data for the remaining variables was performed by using sexspecific mean substitution for continuous variables and mode
imputation for categorical variables. A P value of <0.25 was used
for entry in the multivariable Cox model. Variables were eliminated stepwise until the P value for each was <0.05. A second
multivariable Cox model was done in the same manner, with the
exception that paclitaxel exposure was forced into the model.
HRs and 95% confidence intervals were calculated. P values of
<0.05 were considered statistically significant. With the exceptions of data mapping and heterogeneity assessments, SAS (version 9.4, SAS Institute) was used for the statistical analyses.

RESULTS
Demographic and Baseline Characteristics
Demographic and baseline characteristics were not statistically different in the DCB and PTA arms of the 2
pooled randomized trials (Tables 2 and 3), with 2 exceptions. Patients in the pooled DCB arm were slightly
younger (67.4±9.7 versus 69.4±9.4 years, DCB versus
PTA, P=0.02) and were more often smokers (86.6%
versus 78.8%, DCB versus PTA, P=0.02). The median
exposure of paclitaxel in the DCB-treated patients was
3.9 mg (interquartile range, 2.6–6.5 mg). Study design
and therefore patient demographics were not collected
in the same detail as the RCTs. Therefore, only the RCT
trial patient demographics are reported.

Combining Data Sets
An assessment of poolability among the 7 Stellarex
studies was done in preparation for the identification
of covariates predictive of death after treatment. The
estimated MHR for each of the trials declined at a constant rate. The 2 RCTs, ILLUMENATE EU RCT and ILLUOctober 1, 2019
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a Novel Paclitaxel-coated Percutaneous Angioplasty Balloon)9
are prospective, multicenter, randomized, single-blinded
clinical trials that included control arms of patients treated
with uncoated PTA. ILLUMENATE Global (Global Study of a
Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal
Lesions),13 the in-stent restenosis (ISR) cohort of ILLUMENATE
Global, ILLUMENATE PK9 (Pharmacokinetic Study of Drugcoated Angioplasty Balloons in the Superficial Femoral or
Popliteal Arteries, a pharmacokinetic study of 25 patients),
and ILLUMENATE FIH14 (CVI Drug-coated Balloon First in
Human Trial) are single-arm studies. The SAVER trial (Stellarex
Vascular E-Registry) is an ongoing prospective, multicenter,
real-world registry. All trials were approved by independent
institutional review boards or ethics committees and all
patients provided written informed consent. Adverse events
were reported by the investigational sites, and each site
was monitored for data accuracy and completeness. On-site
monitoring was performed for all trials except SAVER, where
remote monitoring was used. Adverse events occurring within
the follow-up period of each trial were independently adjudicated by a blinded Clinical Events Committee (CEC) that
comprised varied specialists. Variables from the 7 individual
studies were harmonized to account for different variable
names and units and to create one master variable list for all
studies. The data sets were merged using R software (version
3.5.2, R Foundation for Statistical Computing).

Analysis of Mortality in SFA DCB Therapy
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Table 2.

Analysis of Mortality in SFA DCB Therapy

Baseline and Demographic Characteristics of Patients in the 2 RCTs: Categorical Variables
ILLUMENATE EU RCT

Characteristic
Patients in cohort

DCB

ILLUMENATE Pivotal RCT

PTA

DCB

PTA

Pooled RCTs
DCB

PTA

P Value

219

70

200

100

419

170

Male sex

71.7% (157/219)

67.1% (47/70)

56.0% (112/200)

64.0% (64/100)

64.2% (269/419)

65.3% (111/170)

0.85

Hypertension

77.6% (170/219)

82.9% (58/70)

93.5% (187/200)

94.0% (94/100)

85.2% (357/419)

89.4% (152/170)

0.19

Hyperlipidemia

61.6% (135/219)

68.6% (48/70)

88.0% (176/200)

90.0% (90/100)

74.2% (311/419)

81.2% (138/170)

0.09

Myocardial infarction

13.2% (29/219)

17.1% (12/70)

21.0% (42/200)

22.0% (22/100)

16.9% (71/419)

20.0% (34/170)

0.41

Angina

6.8% (15/219)

7.1% (5/70)

15.0% (30/200)

20.0% (20/100)

10.7% (45/419)

14.7% (25/170)

0.21

Congestive heart failure

6.4% (14/219)

8.6% (6/70)

12.0% (24/200)

8.0% (8/100)

9.1% (38/419)

8.2% (14/170)

0.87

Renal insufficiency

9.1% (20/219)

8.6% (6/70)

18.0% (36/200)

17.0% (17/100)

13.4% (56/419)

13.5% (23/170)

>0.99

Chronic pulmonary disease

16.0% (35/219)

10.0% (7/70)

16.0% (32/200)

21.0% (21/100)

16.0% (67/419)

16.5% (28/170)

0.90

Diabetes mellitus

37.0% (81/219)

35.7% (25/70)

49.5% (99/200)

52.0% (52/100)

43.0% (180/419)

45.3% (77/170)

0.65

Previous peripheral
revascularization

20.5% (45/219)

20.0% (14/70)

45.0% (90/200)

48.0% (48/100)

32.2% (135/419)

36.5% (62/170)

0.34

 Current

49.8% (109/219)

48.6% (34/70)

35.5% (71/200)

36.0% (36/100)

43.0% (180/419)

41.2% (70/170)

0.05

 Previous

39.3% (86/219)

34.3% (24/70)

48.5% (97/200)

40.0% (40/100)

43.7% (183/419)

37.6% (64/170)

 Never

11.0% (24/219)

17.1% (12/70)

16.0% (32/200)

24.0% (24/100)

13.4% (56/419)

21.2% (36/170)

 2

15.1% (33/219)

20.3% (14/69)

31.5% (63/200)

35.0% (35/100)

22.9% (96/419)

29.0% (49/169)

 3

83.1% (182/219)

78.3% (54/69)

64.5% (129/200)

60.0% (60/100)

74.2% (311/419)

67.5% (114/169)

 4

1.8% (4/219)

1.4% (1/69)

4.0% (8/200)

5.0% (5/100)

2.9% (12/419)

3.6% (6/169)

 De novo

91.8% (201/219)

90.0% (63/70)

90.5% (181/200)

82.0% (82/100)

91.2% (382/419)

85.3% (145/170)

 Recurrent

8.2% (18/219)

10.0% (7/70)

9.5% (19/200)

18.0% (18/100)

8.8% (37/419)

14.7% (25/170)

Calcification

44.3% (97/219)

41.4% (29/70)

65.7% (130/198)

68.0% (68/100)

54.4% (227/417)

57.1% (97/170)

Smoking

Rutherford category
0.23

Lesion type
0.04

0.58

DCB indicates drug-coated balloon; PTA, uncoated percutaneous transluminal angioplasty; and RCT, randomized, controlled trial.

MENATE Pivotal, had MHRs that were almost identical,
3.95% (95% CI, 2.78%–5.62%) and 3.81% (95% CI,
2.78%–5.63%), respectively (Figure 1). The I2 statistic
was 0.0% (P=0.89), confirming the homogeneity for
the 2 Stellarex RCTs. Given that the protocols, clinical
operations, and baseline demographics were similar
and the effects sizes were almost identical, the 2 RCTs
were pooled for the analysis of mortality after treatment with DCB versus PTA.
The annualized MHR in patients treated with DCB
shows that the ILLUMENATE PK study was an outlier
among the 7 Stellarex studies (Figure 2). The study had
25 patients with 0 deaths. The I2 statistic was 47.3%
(P=0.08) when all 7 studies were included, suggesting
a moderate level of heterogeneity.17 After elimination
of the ILLUMENATE PK study from the analysis, the I2
statistic decreased to 38.6% (P=0.15), indicating moderately low heterogeneity. Eliminating the ILLUMENATE
FIH study decreased the I2 to 27.8% (P=0.24), but the
decision was made to combine all studies, only eliminating ILLUMENATE PK for the Cox modeling of covariates predictive of mortality. Among the 2523 subjects in
1148
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the 7 studies, 25 subjects in the ILLUMENATE PK study
were excluded from combining the studies, as were 3
additional SAVER patients with missing values that precluded sex-specific imputation; accounting for a total
of 28 patients that were excluded from the combined
data set. There were no deaths in the 28 subjects that
were excluded from the combined analysis. In total,
2495 patients remained in the combined analytic data
set of the remaining 6 studies; 2325 DCB-treated subjects and 170 subjects treated with PTA.

All-Cause Mortality
In the 589 patients enrolled in the RCT trials, death occurred in 35 of 419 patients treated with DCB (8.4%)
and 15 of 170 patients treated with PTA (8.8%) within
3 years of the index procedure. There was no significant
difference in all-cause mortality between the 2 cohorts
through full follow-up of 3 years (Figure 3, P=0.86, restricted mean survival time analysis). The proportion of
patients lost to follow-up was low: 3.7% in the ILLUMINATE EU and 2.3% in ILLUMENATE Pivotal RCTs. SubCirculation. 2019;140:1145–1155. DOI: 10.1161/CIRCULATIONAHA.119.040518
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Table 3.

Analysis of Mortality in SFA DCB Therapy

Baseline and Demographic Characteristics of Patients in the 2 RCTs: Continuous Variables
ILLUMENATE Pivotal RCT

Pooled RCT

DCB

PTA

DCB

PTA

DCB

PTA

Patients in cohort

219

70

200

100

419

170

P Value*

Age, y
 N
 Mean

219

70

200

100

419

170

66.8±9.2

69.0±8.7

68.2±10.3

69.7±9.8

67.4±9.7

69.4±9.4

214

67

197

100

411

167

0.7(0.0–1.4)

0.7(0.0–1.5)

0.8(0.0–1.8)

0.8(0.0–1.3)

0.7(0.0–1.8)

0.7(0.0–1.5)

219

70

200

100

419

170

91.3±51.3

94.7±57.3

85.1±41.5

96.1±41.7

88.3±46.9

95.5±48.5

0.02

Ankle brachial
 N
 Median

0.63

Lesion length, mm
 N
 Mean

0.10

Reference vessel diameter, mm
 N
 Mean

218

70

200

100

418

170

5.0±0.8

4.8±0.7

4.9±0.9

5.2±1.1

4.9±0.9

5.0±0.9

218

70

200

100

418

170

81.7±14.3

83.1±14.2

73.9±16.9

74.8±17.0

77.9±16.0

78.2±16.4

0.44

Diameter stenosis, % reduction
 N
 Mean

0.87

Paclitaxel dose, mg
 N
 Median

219

70

200

100

419

NA

4.3(1.1–15.8)

NA

3.9(1.3–9.4)

NA

3.9(1.1–15.8)

NA

NA

Data are expressed as mean±SD or median (range). DCB indicates drug-coated balloon; PTA, percutaneous transluminal angioplasty; NA, not applicable; and RCT,
randomized, controlled trial.*P value for the comparison of the DCB and PTA cohorts of the pooled RCTs.

jects voluntarily withdrawing before completion in the
studies was 12.2% of ILLUMENATE EU and 7.0% of ILLUMENATE Pivotal trials. The 1-year (360-day) Kaplan–
Meier estimate of all-cause mortality was 1.8±0.7%
(estimate±SE) in the DCB cohort and 1.3±0.9% in the
PTA cohort. At 2 years (720 days), all-cause mortality
was 6.5±1.3% in the DCB cohort versus 5.9±1.9% in
the PTA cohort. At 3 years (1080 days), all-cause mortality was 9.3±1.5% in the DCB cohort and 9.9±2.4%
in the PTA cohort.
In the cohort of 2325 DCB-treated patients from the
6 combined studies, 80 deaths (3.4%) occurred through
3 years. The 1-, 2-, and 3-year Kaplan–Meier estimates

of all-cause mortality were 2.0±0.4%, 5.6±0.7%, and
8.0±0.9%, respectively, in the 6 combined studies (Figure 4). The corresponding estimates for the 1906 DCBtreated patients enrolled in the 4 combined nonrandomized studies were not clinically different from the rates in
the RCTs; 2.1±0.4% at 1 year, 4.9±0.8% at 2 years, and
7.0±1.1% at 3 years after treatment (Figure 5).

Adjudicated Causes of Death
The causes of death are summarized in Table 4,
categorized by MedDRA System Organ Classes. The
CEC-adjudicated cause of death through 3 years was

Figure 1. Hazard rates for mortality for
drug-coated balloon arms of the 2 randomized, controlled trials (RCTs).
The Pivotal study and EU RCT had nearly identical hazard rates with an overall I2 of 0.0%,
indicative of homogeneity. EU RCT indicates
CVI Drug-coated Balloon European Randomized Clinical Trial; and PIVOTAL, Pivotal Trial
of a Novel Paclitaxel-coated Percutaneous
Angioplasty Balloon.

Circulation. 2019;140:1145–1155. DOI: 10.1161/CIRCULATIONAHA.119.040518
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Figure 2. Hazard rates for mortality in
patients treated with drug-coated balloons.
A, The hazard rates for mortality in patients
treated with drug-coated balloons (DCBs) in the
7 Stellarex studies. Patients treated with DCBs
in the 7 Stellarex studies had an overall I2 of
47.3%, consistent with moderate heterogeneity. ILLUMENATE PK was an outlier, with a
hazard rate of 0.10. B, Annualized hazard rates
for mortality for patients treated with DCBs in
the 6 Stellarex studies. After elimination of the
PK study, the overall I2 decreased to 38.6%,
reflecting moderately low heterogeneity in the
6 remaining studies. EU RCT indicates CVI Drugcoated Balloon European Randomized Clinical
Trial; FIH, first in human; GLOBAL, Global Study
of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions; ISR, in-stent
restenosis; PIVOTAL, Pivotal Trial of a Novel
Paclitaxel-coated Percutaneous Angioplasty
Balloon; PK, pharmacokinetic; RCT, randomized,
controlled trial; and SAVER-E, Stellarex Vascular
E-Registry.

cardiovascular in 20 patients (25%) and noncardiovascular in 60 patients (75%). Among the non–cardiovascular-related deaths in the patients treated with DCB, 17
(21%) were of undetermined cause at the time of this

analysis. In the 15 deaths in the PTA cohort, the adjudicated cause was cardiovascular in 4 (27%) and noncardiovascular in the remaining 11 (73%). The higher
proportion of deaths of undetermined cause in the non-

Figure 3. Survival in the pooled randomized,
controlled trials (RCTs).
The pooled RCTs show no significant differences in the
survival rates in the 2 groups through 3-year (1080day) follow-up. For further information about pooling,
refer to the combining data sets section of the article.
The P value tests the null hypothesis that restricted
mean survival time (RSMT) for the 2 curves are equal vs
the alternative that they are not equal. DCB indicates
drug-coated balloon; and PTA, uncoated percutaneous
transluminal angioplasty.
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randomized DCB cohort was attributable to yet undetermined causes of death in the ongoing SAVER registry.
The most common CEC-adjudicated cause of death
after DCB treatment was a cardiac disorder, responsible
for 19 of 80 deaths (23.8%), followed by neoplasms
(18/80 deaths, 22.5%). In the PTA cohort, general disorders were the most common cause of death (5/15,
33.3%), followed by cardiac disorders (4/15, 26.7%)
and neoplasms (2/15, 13.3%). There were no deviceor procedure-related deaths adjudicated in the entire
series of 2523 patents.

Predictors of Mortality After DCB
Treatment
The Cox proportional hazards analysis of mortality in
the 6 combined studies included 2495 patients: 589
patients from the 2 RCTs and 1906 patients from the 4
nonrandomized studies. The univariate analysis includ-

ed 16 candidate baseline variables, 7 of which had HRs
with P values of <0.05 (Table 5).
Among the 16 candidate variables, 10 had univariate
HRs with P values of <0.25 and were entered into the
multivariable Cox proportional hazards model. Variables
were eliminated stepwise until the P value for each remaining variable was <0.05. The final model identified
4 significant predictors of mortality (Table 6); age (HR,
1.06; 95% CI, 1.04–1.08; P<0.001), diabetes mellitus
(HR, 1.43; 95% CI, 1.01–2.01; P=0.04), congestive
heart failure (HR, 1.86; 95% CI, 1.11–3.12; P=0.02),
and renal insufficiency (HR, 2.00; 95% CI, 1.33–3.01;
P<0.001). When treatment (DCB versus PTA) was
forced into the model to assess its effect on the risk of
death, the use of a DCB was not a predictor of mortality
(HR, 1.18; 95% CI, 0.75–1.87; P=0.47). Similarly, when
paclitaxel exposure (mg) was forced into the model as a
continuous variable, exposure did not predict mortality
(HR, 1.04; 95% CI, 0.98–1.10; P=0.23).

Figure 5. Survival through 3 years in the 4 nonrandomized, pooled studies.
The 3-year mortality estimate for the ILLUMENATE FIH
(CVI Drug-coated Balloon First in Human Trial), ILLUMENATE Global (Global Study of a Drug-Coated Balloon
to Treat Obstructive SFA and/or Popliteal Lesions),
Global-ISR (in-stent restenosis), and SAVER (Stellarex
Vascular E-Registry) studies was 7.0% by Kaplan–Meier
methodology. DCB indicates drug-coated balloon.
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Figure 4. Survival through 3 years (1080 days) in
the 6-study pooled data set.
The ILLUMENATE PK study (Pharmacokinetic Study of
Drug-coated Angioplasty Balloons in the Superficial
Femoral or Popliteal Arteries) was excluded because
there were no deaths. The Kaplan–Meier estimates
are reported for each year. DCB indicates drug-coated
balloon.

ORIGINAL RESEARCH
ARTICLE

Gray et al

Analysis of Mortality in SFA DCB Therapy

Table 4. Causes of Death in Patients Treated With Paclitaxel-Coated
Balloons as Adjudicated by the Clinical Events Committee (MedDRA
System-Organ Classes)

Cause of Death
Cardiac
disorders

Pooled
Studies*

Non-RCTs*

DCB
n=2325

DCB
n=1906

1/80 (1%)

General
disorders

8/80 (10%)

0/45 (0%)
5/45 (11%)

Pooled RCTs
DCB
n=419

PTA
n=170

8/35 (23%)

4/15 (27%)

1/35 (3%)
3/35 (9%)

1/15 (7%)
5/15 (33%)

Hepatobiliary
disorders

1/80 (1%)

0/45 (0%)

1/35 (3%)

1/15 (7%)

Infections and
infestations

5/80 (6%)

2/45 (4%)

3/35 (9%)

0/15 (0%)

Injury/poisoning/
procedural

1/80 (1%)

Metabolism and
nutritional
Neoplasms
benign,
malignant

Hazard Ratio
(95% CI)

Covariate

19/80 (24%) 11/45 (24%)

Gastrointestinal
disorders

Table 5. Univariate Cox Proportional Hazards Analysis of Baseline and
Demographic Predictors of Mortality

0/45 (0%)

1/80 (1%)

0/45 (0%)

18/80 (23%)

6/45 (13%)

1/35 (3%)
1/35 (3%)

0/15 (0%)
0/15 (0%)

12/35 (34%) 2/15 (13%)

Nervous system
disorders

1/80 (1%)

1/45 (2%)

0/35 (0%)

0/15 (0%)

Renal and
urinary disorders

0/80 (0%)

0/45 (0%)

0/35 (0%)

1/15 (7%)

Respiratory/
thoracic/
mediastinal

7/80 (9%)

3/45 (7%)

4/35 (11%)

1/15 (7%)

Vascular
disorders

1/80 (1%)

0/45 (0%)

1/35 (3%)

0/15 (0%)

0/35 (0%)

0/15 (0%)

35/419
(8.4%)

15/170
(8.8%)

P Value

Male sex

1.08 (0.76–1.55)

0.66

Age, per year

1.07 (1.05–1.09)

<0.01

Lesion length, per mm

1.00 (0.99–1.00)

0.14

Hypertension

0.98 (0.63–1.54)

0.94

Hyperlipidemia

0.97 (0.66–1.44)

0.90

Myocardial infarction

0.98 (0.62–1.55)

0.93

Angina

1.01 (0.58–1.76)

0.97

Renal insufficiency

2.93 (1.98–4.34)

<0.01

Congestive heart failure

2.32 (1.40–3.86)

0.01

Diabetes mellitus

1.45 (1.03–2.03)

0.03

Smoking history*

0.58 (0.39–0.86)

0.01

Previous peripheral vascular procedure

1.26 (0.90–1.79)

0.18

Rutherford 2 vs 3

0.79 (0.52–1.22)

<0.01

Rutherford 4 vs 3

2.15 (1.22–3.79)

Rutherford 5 vs 3

4.53 (1.66–12.38)

Lesion type, de novo

0.72 (0.45–1.16)

0.17

Calcification

1.47 (1.02–2.11)

0.04

Paclitaxel dose, per mg

1.02 (0.96–1.08)

0.53

*Hazard ratio for smokers, current and prior.

A recent systematic review and summary-level metaanalysis by Katsanos et al12 raised safety concerns
related to the use of paclitaxel balloons and stents
for treating femoropopliteal arterial disease. The current analysis was undertaken to further confirm the
previously reported safety profile of the Stellarex
DCB.7,9,13,14,18,19 In contrast to the methodology used
by Katsanos, the current study used an independent
analysis of patient-level data, a single DCB device, and
poolable studies. ILLUMENATE PK, a small study with
no deaths, was excluded from the analysis because of
its heterogeneity. The present findings differ substantially from those of the Katsanos meta-analysis. The
current study of the combined Stellarex RCTs showed

that patients in the DCB cohort had mortality rates
comparable to those in the PTA cohort, an observation that must be considered in the context of the size
of the ILLUMENATE studies, none of which were adequately powered to detect differences in long-term
mortality. Nonetheless, pooling of patients from the
RCT data sets strengthens the validity of the analyses. The current findings confirm and are consistent
with the previously reported findings from the ILLUMENATE femoropopliteal clinical program that demonstrated the strong safety and efficacy DCB at 1 and
2 years.9,14,19
Paclitaxel is a cytostatic and cytotoxic agent commonly used for cancer chemotherapy. With the advent
of local drug delivery technologies, paclitaxel-eluting
coronary stents were demonstrated to be effective in
the reduction of clinical restenosis in percutaneous coronary interventions.20 However, first-generation coronary paclitaxel-eluting coronary stents were subject
to slightly higher rates of stent thrombosis than bare
metal stents.21 Despite this hazard, paclitaxel-eluting
stents have not been shown to have excess mortality in comparison with bare metal stents.22–24 When
used in the femoropopliteal arteries, paclitaxel-coated balloons such as the Stellarex DCB have reduced
restenosis, yielding improved long-term patency.3,14
Paclitaxel exerts its antirestenotic properties through
the prevention of smooth muscle cell proliferation
by blocking mitosis.25–27 Paclitaxel DCBs used in the
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Undetermined
Total deaths
through 3 y

17/80 (21%) 17/45 (38%)
80/2325
(3.4%)

45/1906
(2.4%)

DCB indicates drug-coated balloon; MedDRA, Medical Dictionary for
Regulatory Activities; PTA, percutaneous transluminal angioplasty; and RCT,
randomized, controlled trial.
*Data comprise pooled data sets. There were no deaths in the 28 patients
excluded from the pooled analysis.
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Multivariable Cox Proportional Hazards Model for Mortality
Hazard Ratio (95% CI)

P Value

 Age, per year

1.06 (1.04–1.08)

<0.01

 Congestive heart failure

1.86 (1.11–3.12)

0.02

 Diabetes mellitus

1.43 (1.01–2.01)

0.04

 Renal Insufficiency

2.00 (1.33–3.01)

<0.01

 Age, per year

1.06 (1.04–1.08)

<0.01

 Congestive heart failure

1.89 (1.12–3.19)

0.02

 Diabetes mellitus

1.45 (1.03–2.04)

0.04

 Renal insufficiency

2.03 (1.35–3.06)

<0.01

 Paclitaxel dose, per mg

1.04 (0.98–1.10)

0.23

With drug dose forced into the model

Multivariate predictors were chosen with a stepwise procedure using an
entry criterion 0.25 and a stay criterion of 0.05.

femoropopliteal segment have consistently demonstrated improved target vessel patency, with significant reduction in late lumen loss and target vessel
revascularization.4,6,7,9,10,28–30
Paclitaxel, when delivered systemically for breast,
lung, and other malignancies, is used in significantly
higher concentrations than the doses used in peripheral
vascular applications.5 In larger doses, the common side
effects of paclitaxel include anemia, gastrointestinal
symptoms, and renal impairment. Other less common
side effects include allergic/hypersensitivity reactions,
liver toxicity, neurotoxicity, and cardiac rhythm changes.
Outside the toxic reactions leading to death in chemotherapy drug trials for patients with cancer, there are
no substantive preclinical or patient-level clinical studies
correlating the mechanism of action of paclitaxel with
long-term side effects leading to death, including those
associated with treatment of PAD.
The meta-analysis by Katsanos et al12 concluded
that there is an increased late mortality risk after the
application of paclitaxel-coated balloons and stents
in the femoropopliteal arteries of the lower limbs.
However, the study has several limitations. The study
combined RCTs and examined multiple devices of different applications and doses, including both DCBs
and drug-eluting stents.12 Patient-level data were unavailable to the authors, precluding a granular level of
detail for causes of death. In addition, the reporting of
death rates used by the study was inconsistent; some
studies reported event frequency within time intervals, whereas others reported the rates cumulatively.12
Last, despite the inclusion of 28 RCTs in the analysis,
the mortality conclusions were based on considerably
fewer presentations and publications where extended
follow-up was available.
The findings of 2 recently published comparisons
of DCB to PTA failed to support the conclusions of
Katsanos. Schneider et al31 published outcomes of
Circulation. 2019;140:1145–1155. DOI: 10.1161/CIRCULATIONAHA.119.040518

Limitations
The analysis was limited by the size of the 2 combined
RCTs with many fewer patients in the PTA arms, 170
versus 419, and the ongoing follow-up in some of the
trials without complete follow-up in all patients, as
well. Even together, the trials lacked enough power
to ensure the absence of mortality differences. An adequately powered study to identify a clinically relevant
reduction of 50% from the annual rates from our DCB
studies would require a sample size of from 1600 to
6000 randomly assigned patients with at least 3 years
October 1, 2019
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Without forcing drug dose into the model

a patient-level meta-analysis comprising 2 RCTs and
2 single-arm trials of 1980 patients: 1837 patients
treated with a higher-dose paclitaxel-coated balloon
from a single manufacturer and 143 patients treated
with uncoated PTA. Overall, there was no statistically
significant difference in all-cause mortality between
patients treated with DCB versus PTA through 5-year
follow-up (15.1% versus 11.2%, P=0.09).31 In the
second recent publication, Secemsky and colleagues32
evaluated all-cause mortality in a retrospective analysis of 16 560 Medicare and Medicaid beneficiaries
treated for femoropopliteal disease during calendar
year 2016. The authors were unable to detect an association between all-cause mortality and the use of
DCBs or drug-eluting stents, with a HR of 0.97 (95%
CI, 0.91–1.04; P=0.20). The failure to find a difference, however, is confounded by median follow-up
of ≈1 year in this study. This duration may have been
too short to observe differences in mortality, differences that became evident at 2 years in the analysis
of Katsanos et al.33
Currently, there are many RCTs with superior efficacy results for DCB therapy over uncoated PTA for
femoropopliteal lesions.,4,6,7,9,10,13,14,19,28 These DCB trials have often met their primary safety outcomes and
shown durable safety outcomes. Although DCBs introduce risks as with any endovascular procedure, study
results confirm long-term patency, thereby reducing
the rate of reinterventions. Current opinion suggests
that the benefits continue to outweigh the risks associated with DCB.1,34,35
We recommend further adequately powered metaanalyses of RCTs studying paclitaxel-coated DCBs to
test the generalizability of the results presented here.
Further analyses with cross-industry collaboration, including any associations between device-specific characteristics (eg, paclitaxel dosage, coating morphology)
may be warranted. In light of questions raised by the
Katsanos meta-analysis, continued enrollment and
long-term follow-up of patients treated with DCBs is
needed to further reinforce the safety profile of paclitaxel-coated DCBs for the treatment of femoropopliteal PAD.
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of follow-up. Although samples size calculations depend on the eligibility criteria and mortality rates that
may differ from the current study, an adequately powered study would still be much larger than the current
DCB trials. Also, in our comparison of the 2 RCTs, we
assumed that patients in the PTA arms were paclitaxel-naïve. However, some patients who received PTA
may have been exposed to paclitaxel with other DCBs
or drug-eluting stents before enrollment, for instance
in the contralateral limb, or during the follow-up period. Our analysis may then underestimate the number of patients treated with any paclitaxel, a limitation
inherent with many analyses in the field. In addition,
in some studies, as many as 3% of patients were lost
to follow-up. Because the mortality rates are low, this
may represent a limitation to statistical analysis. Separately, when combining the studies from the Stellarex
femoropopliteal clinical program, discrepancies exist
between the manner with which data were collected as
part of RCTs and data were collected for single-arm trials and registries. Heterogeneity among trials could not
be completely eliminated, while adding more events to
the analysis resulted in a loss of some degree of homogeneity in the aggregate analytic data set. Finally,
commercially available DCBs differ in paclitaxel dosage,
excipient, and other properties specific to each device.
Therefore, the current observations with the Stellarex
DCBs may not be applicable to other DCBs.

Conclusions
Results from this systematic combined analysis of 3-year
data from the Stellarex femoropopliteal clinical program
demonstrate no significant difference in mortality rates
in patients treated with a paclitaxel DCB and PTA. No
device- or procedure-related deaths were reported. Although further research with larger RCT data sets is encouraged to test the generalizability of these results, the
data presented in this article do not confirm the findings
of Katsanos et al. Within the context of studies that were
not powered to detect mortality differences, Stellarex
DCB remains a viable alternative in the treatment of PAD.
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